Video

PCa focal therapy: Who are the best candidates?

In this video, Scott Eggener, MD, outlines which patients are the best candidates for focal therapy for prostate cancer, and discusses the differences in follow-up for patients treated with focal therapy compared with those undergoing active surveillance.

In this video, Scott Eggener, MD, of the University of Chicago, outlines which patients are the best candidates for focal therapy for prostate cancer, and discusses the differences in follow-up for patients treated with focal therapy compared with those undergoing active surveillance.

 

More videos from Urology Times:

Study will test targeted PCa therapies based on genomic alterations

LUGPA President Dr. Richard Harris: 2020 challenges

Dr. Mara Holton discusses LUGPA's recent policy victories, upcoming challenges

Related Videos
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
DNA helix | Image Credit: © BillionPhotos.com - stock.adobe.com
Woman typing on laptop | Image Credit: © Gorodenkoff - stock.adobe.com
Related Content
Targeted microwave ablation shows precision, safety in localized prostate cancer
November 21st 2024

Targeted microwave ablation shows precision, safety in localized prostate cancer

Hannah Clarke
In the recent news release, Koelis reported that the final patient was enrolled in the VIOLETTE study in September 2024.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Study indicates overtreatment of men with prostate cancer and limited life expectancy
November 20th 2024

Study indicates overtreatment of men with prostate cancer and limited life expectancy

Hannah Clarke
“Prostate cancer patients with life expectancies of less than 5 or 10 years were being subjected to treatments that can take up to a decade to significantly improve their chances of surviving cancer, despite guidelines recommending against treatment," says Timothy J. Daskivich, MD.
Dr. Schwen on focal therapies for prostate cancer
January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
Study characterizes long-term impact of prostate cancer treatment
November 8th 2024

Study characterizes long-term impact of prostate cancer treatment

Hannah Clarke
“Our study is distinguished by long follow-up, out to 12 years, looking at a broad spectrum of key complications," says Joseph M. Unger, PhD.
Phase 1/2 trial of ONCT-534 in mCRPC has been terminated
November 7th 2024

Phase 1/2 trial of ONCT-534 in mCRPC has been terminated

Hannah Clarke
The decision was based on an interim readout from the trial, which showed that ONCT-534 did not lead to any clinically meaningful improvement of disease.
© 2024 MJH Life Sciences

All rights reserved.